Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

INBRX-109

Phase 2Small molecule

IInhibrx Biosciences, Inc

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Conventional ChondrosarcomaActive, not recruiting

Conventional ChondrosarcomaPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Conventional Chondrosarcoma

NCT04950075

Q2 2029

Phase 1Recruiting

Ewing Sarcoma

NCT03715933

Clinical

Trials by Indication[1]

Ewing sarcoma1 trial

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting·IInhibrx Biosciences, Inc·Phase 1·NCT03715933·411 enrolled

Conventional Chondrosarcoma1 trial

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Active, not recruiting·IInhibrx Biosciences, Inc·Phase 2·NCT04950075·206 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for INBRX-109. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INBRX-109 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INBRX-109. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inhibrx Biosciences, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInhibrx Biosciences, Inc

Related News